Pomaglumetad methionil anhydrous
As of the edition of 20 October 2026, Pomaglumetad methionil anhydrous is a small molecule: stopped in 2020; acts on GRM2 and GRM3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Small molecule
- Registered trials
- 23, 8 stopped early
- Disease areas
- Mental health; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Pomaglumetad methionil anhydrous.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 12 | 9 | 0 | 3 |
| Phase 2 | 6 | 5 | 0 | 1 |
| Phase 3 | 5 | 1 | 0 | 4 |
| All trials | 23 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Denovo Biopharma | Lead sponsor of trials | 2005 to now |
| Eli Lilly | Lead sponsor of trials | 2012 to now |